- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
UCB SA ADR (UCBJY)
UCB SA ADR stock price live, this page displays OTC UCBJY stock exchange data. View the UCBJY premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the UCB SA ADR real time stock price chart below.
What Is the UCB SA ADR Stock Price Today?
The UCB SA ADR stock price today is 149.54.
What Is the Stock Symbol for UCB SA ADR?
The stock symbol for UCB SA ADR is "UCBJY."
What Stock Exchange Does UCB SA ADR Trade On?
UCB SA ADR is listed and trades on the OTC Markets stock exchange.
Is UCB SA ADR a Good Stock to Buy?
Determining whether UCB SA ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the UCBJY quote. (ISIN: US9034801012)
What Is the UCB SA ADR Stock Price Today?
The UCB SA ADR stock price today is 149.54.
What Is the Stock Symbol for UCB SA ADR?
The stock symbol for UCB SA ADR is "UCBJY."
What Stock Exchange Does UCB SA ADR Trade On?
UCB SA ADR is listed and trades on the OTC Markets stock exchange.
Is UCB SA ADR a Good Stock to Buy?
Determining whether UCB SA ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the UCBJY quote. (ISIN: US9034801012)
149.54
-1.17(-0.78%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
149.37
152.13
52 wk Range
89.00
168.76
UCBJY is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
149.37152.13
52 wk Range
89.00168.76
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.35%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.35%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
UCBJY Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
162.20
Upside
+8.47%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a low P/E ratio relative to near-term earnings growth
- UCB to acquire Neurona Therapeutics for up to $1.15 billion
- Investing.com
Pro
- UCB to acquire Candid Therapeutics for up to $2.2 billion
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Buy
Analyst Ratings
2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 162.20
(+8.47% Upside)
Earnings
Latest Release
May 29, 2026
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
Compare UCBJY to Peers and Sector
Metrics to compare | UCBJY | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipUCBJYPeersSector | |
|---|---|---|---|---|
P/E Ratio | 31.9x | 21.0x | −0.5x | |
PEG Ratio | 0.69 | 0.36 | 0.00 | |
Price/Book | 4.6x | 4.1x | 2.6x | |
Price / LTM Sales | 6.4x | 3.5x | 3.0x | |
Upside (Analyst Target) | 8.5% | 14.0% | 58.7% | |
Fair Value Upside | Unlock | 14.7% | 10.3% | Unlock |
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. In addition, the company offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx to treat plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; Fintepla for the treatment of Dravet and Lennox-Gastaut syndrome; and RYSTIGGO and ZILBRYSQ to treat people living with generalized myasthenia gravis. Further, it develops KYGEVVI (doxecitine/doxribtimine) for thymidine kinase 2 deficiency disorder; fenfluramine to treat CDKL5 deficiency disorder, and RETT-Syndrome; dapirolizumab pegol for systemic lupus erythematosus; STACCATO alprazolam for treating stereotypical prolonged seizures; bepranemab to treat Alzheimer’s disease; and UCB9741 for atopic dermatitis, non cystic fibrosis bronchiectasis, and chronic obstructive pulmonary disease. Additionally, it engages in the contract manufacturing activities. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the UCB ADR (UCBJY) Stock Price Today?
The UCB ADR stock price today is 149.54 USD.
What Stock Exchange Does UCB ADR Trade On?
UCB ADR is listed and trades on the OTC Markets.
What Is the Stock Symbol for UCB ADR?
The stock symbol for UCB ADR is "UCBJY."
Does UCB ADR Pay Dividends? What’s The Current Dividend Yield?
The UCB ADR dividend yield is 0.35%.
What Is the UCB ADR Market Cap?
As of today, UCB ADR market cap is 57.24B USD.
What Is UCB ADR's Earnings Per Share (TTM)?
The UCB ADR EPS (TTM) is 8.03.
When Is the Next UCB ADR Earnings Date?
UCB ADR will release its next earnings report on Jul 30, 2026.
From a Technical Analysis Perspective, Is UCBJY a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has UCB ADR Stock Split?
UCB ADR has split 0 times.
How Many Employees Does UCB ADR Have?
UCB ADR has 9765 employees.
What is the current trading status of UCB ADR (UCBJY)?
As of Jun 07, 2026, UCB ADR (UCBJY) is trading at a price of 149.54 USD, with a previous close of 150.71 USD. The stock has fluctuated within a day range of 149.37 USD to 152.13 USD, while its 52-week range spans from 89.00 USD to 168.76 USD.
What Is UCB ADR (UCBJY) Price Target According to Analysts?
The average 12-month price target for UCB ADR is 162.20 USD, with a high estimate of 163.95506912 USD and a low estimate of 160.45046083 USD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +8.47% Upside potential.
What Is the UCBJY After Hours Price?
UCBJY's last after hours stock price is 146.51 USD, the stock has decreased by 0.75, or 0.51%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.